Octreotide treatment

Biliary cholesterol saturation index (CSI) in nonacromegalic patients with cholesterol GBS (CH-GBS), acromegalic patients with Octreotide-associated GBS (OT-GBS), and stone-free patients before Octreotide treatment (No OT-GBS). "Hie value of CSI = 1.0 indicates the limit of cholesterol solubility points above the line are supersaturated, whereas those below the line are unsaturated with cholesterol. (All graphs show mean values SEMs.) Data taken from reference 18. 

Graph 8.5 Paired data for the proportion of DCA (percentage of total bile acids) in bile before and during Octreotide treatment (SOOpg/day for 8 months). Data taken from reference 18. 

Mechanism for the Increase in the /o Biliary DCA Conjugates in Bile during Octreotide Treatment... 

Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A, Jensen RT. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002 94(2) 331 13. 

Originally isolated from the hypothalamus, somatostatin is a small polypeptide that is also found in neurons throughout the body, as well as in the intestine and pancreas. Somatostatin therefore predictably has a number of actions. Octreotide [awk TREE oh tide] is a synthetic octapeptide analog of somatostatin. It has a much longer half-life than the natural compound and has found use in the treatment of acromegaly caused by hormone-secreting tumors, and secretory diarrhea associated with tumors producing the vasoactive intestinal peptide (VIP). Adverse effects of octreotide treatment are flatulence, nausea, and steatorrhea. 

FROIDEVAUX, S., et al.. Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumour cells implanted into mice during octreotide treatment. Cancer Res. 59 (1999) 3652-3657. 

Paran H, Mayo A, Paran D. Octreotide treatment in patients with severe acute pancreatitis. Dig Dis Sci 2000 45 2247-2251. 

Ezzat S, Snyder PJ, Young WF, et al. Octreotide treatment of acromegaly A randomized, multicenter study. Ann Intern Med 1992 117 211-218. 

Padayatty SJ, Perrins EJ, Belchetz PE. Octreotide treatment increases exercise capacity in patients with acromegaly. Eur J Endocrinol 1996 134 554-559. 

In addition to its effect on GH secretion, octreotide can decrease tumor size—although tumor growth generally resumes after octreotide treatment is stopped. Octreotide also has significant inhibitory effects on thyrotropin secretion, and it is the treatment of choice for patients who have thyrotrope adenomas that oversecrete thyroid-stimulating hormone (TSH) and who are not good candidates for surgery. 

Long-term infusion in infants An open-label study of 15 Japanese infants with diazoxide-unresponsive KATP-channel hyperinsulinism found that long-term, continuous, subcutaneous octreotide treatment appeared to be safe and efficacious [78 ]. Transient gastrointestinal problems and growth deceleration at higher doses of octreotide were the primary adverse events encountered in the study. Given the small sample size and possibility of serious side... 

---